Clinical study of Pabolizumab combined with radiotherapy for neoadjuvant therapy of advanced low and middle rectal cancer

Efficacy and safety of Pabolizumab combined with radiotherapy versus concurrent chemoradiotherapy for neoadjuvant therapy in advanced low and middle rectal cancer: a multicenter, open, randomized controlled clinical trail

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045988

Enrollment

Unknown

Registered

2021-05-01

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

control group:concurrent radiochemotherapy

experimental group:Paborizumab combined with radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Rectum cancer diagnosed by histopathology; 2. The clinical stage of T3+N0M0 or TXN+M0; 3. Agree to conduct MMR / MSI test and the result is dMMR / MSI-H; 4. The tumor is located within 12cm of the anus; 5. Can tolerant immunotherapy, chemotherapy and radiotherapy; 6. The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up.

Exclusion criteria

Exclusion criteria: 1. Participating in other clinical investigates; 2. Other chemotherapy history.

Design outcomes

Primary

Measure	Time frame
tumor regression grading;	—

Secondary

Measure	Time frame
R0 resection rate;serious adverse event;Immune related adverse events;overall response rate;overall survival;	—

Countries

China

Contacts

Public ContactZhang Chaojun

The First Medical Center of the PLA General Hospital

zcjdlyxzx@163.com+86 18600317036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026